[{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"CrystalGenomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Polmacoxib","moa":"Carbonic anhydrase I | Cyclooxygenase-2 | Carbonic anhydrase II||Carbonic anhydrase II | Carbonic anhydrase I | Cyclooxygenase-2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"CrystalGenomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CrystalGenomics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CrystalGenomics \/ Undisclosed"},{"orgOrder":0,"company":"Kolon Life Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Tissuegene-C","moa":"Chondrocyte","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon Life Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kolon Life Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kolon Life Science \/ Undisclosed"},{"orgOrder":0,"company":"Kolon Life Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Tissuegene-C","moa":"Chondrocyte","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon Life Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kolon Life Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kolon Life Science \/ Undisclosed"},{"orgOrder":0,"company":"Kolon Life Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Tissuegene-C","moa":"Chondrocyte","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon Life Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kolon Life Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kolon Life Science \/ Undisclosed"},{"orgOrder":0,"company":"Kolon Life Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Tissuegene-C","moa":"Chondrocyte","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon Life Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kolon Life Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kolon Life Science \/ Undisclosed"},{"orgOrder":0,"company":"Kolon Life Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Tissuegene-C","moa":"Chondrocyte","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon Life Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kolon Life Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kolon Life Science \/ Undisclosed"},{"orgOrder":0,"company":"HANDOK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ketoprofen","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HANDOK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HANDOK \/ Undisclosed"},{"orgOrder":0,"company":"YooYoung Pharmaceutical Co., Ltd","sponsor":"CliPSBnC","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"YooYoung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YooYoung Pharmaceutical Co., Ltd \/ CliPSBnC","highestDevelopmentStatusID":"10","companyTruncated":"YooYoung Pharmaceutical Co., Ltd \/ CliPSBnC"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Risedronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CT-P41","moa":"IL-6 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"HU-014","moa":"SNAP25","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Huons CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huons CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"HU-014","moa":"SNAP25","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Huons CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huons CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Huons CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huons CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Gel","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Biosolution","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Costal Chondrocyte","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosolution","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Biosolution \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biosolution \/ Undisclosed"},{"orgOrder":0,"company":"Biosolution","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Costal Chondrocyte","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosolution","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Biosolution \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biosolution \/ Undisclosed"},{"orgOrder":0,"company":"SEWON CELLONTECH CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Autologous Cultured Chondrocyte","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"SEWON CELLONTECH CO LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SEWON CELLONTECH CO LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SEWON CELLONTECH CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"LBSA0103","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SKCPT","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Chemicals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SK Chemicals \/ Undisclosed"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SP5M001","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shin Poong Pharm Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shin Poong Pharm Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Kolon Life Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Tonogenchoncel-L","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon Life Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kolon Life Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kolon Life Science \/ Undisclosed"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Vitis Vinifera Extract","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"YooYoung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"YYD302","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"YooYoung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"YooYoung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"YYD302","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"YooYoung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Obodence (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia. It is a RANK ligand inhibitor, which is being evaluated for bone loss in adult men.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          November 15, 2024

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : SP5M001 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Thumb.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 13, 2024

                          Lead Product(s) : SP5M001

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : SKCPT is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 05, 2023

                          Lead Product(s) : SKCPT

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Celecoxib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 05, 2022

                          Lead Product(s) : Celecoxib

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : CliPSBnC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : HU-014 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Muscle Spasticity.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          March 22, 2022

                          Lead Product(s) : HU-014

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : CartiLife (Autologous Costal Chondrocyte) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cartilage Diseases.

                          Product Name : CartiLife

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          September 21, 2021

                          Lead Product(s) : Autologous Costal Chondrocyte

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : CT-P41 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoporosis, Postmenopausal.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 17, 2021

                          Lead Product(s) : CT-P41

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Prolia is Amgen’s treatment for skeletal diseases, osteoporosis and bone loss of cancer patients. The company began to conduct the trial in November, comparing the efficacy and safety of SB16 with the original drug on 432 post-menopausal osteoporosis p...

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          December 14, 2020

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Denosumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoporosis, Postmenopausal.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          December 11, 2020

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Ketoprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 09, 2020

                          Lead Product(s) : Ketoprofen

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank